The ravel trial. Zero percent restenosis: A cardiologist's dream comes true!

Revista Espanola de Cardiologia

Volumn 55, Issue 5, 2002, Pages 459-462

  Regar, Evelyn ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; BALLOON CATHETER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; CORONARY STENT; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; LYMPHOCYTE PROLIFERATION; RESTENOSIS; SLOW RELEASE FORMULATION; T LYMPHOCYTE; RANDOMIZED CONTROLLED TRIAL; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; CORONARY RESTENOSIS; HUMANS; RANDOMIZED CONTROLLED TRIALS; STENTS;

EID: 0036017316     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(02)76634-7     Document Type: Editorial

References (16)

1. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor
2. Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels
3. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement
4. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells
5. Rapamycin inhibits vascular smooth muscle cell migration
6. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model
7. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study
8. Mid-(4 months) and long-term (1 year) QCA and three-dimensional IVUS follow-up after implantation of sirolimus-coated stent in human coronary arteries
9. Coronary restenosis elimination with a sirolimus eluting stent. First European human experience with six month angiographic and intravascular ultrasonic follow-up
10. Revascularization with sirolimus-eluting versus an uncoated stent in patients with coronary artery disease
11. The RAVEL study: A randomized study with the sirolimus coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions
12. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the multicenter ultrasound stenting in coronaries study (MUSIC Study)
13. Clinical and angiographic results with the Multi-Link stent implanted under intravascular ultrasound guidance (West-2 Study)
14. Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS Study)
15. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle
16. Gene expression profiling of human stent-induced neointima by cDNA array analysis of microscopic specimens retrieved by helix cutter atherectomy: Detection of FK506-binding protein 12 upregulation